Loading
A phase 2 trial of adebrelimab and rivoceranib (apatinib) in lung cancer, run by Tang-Du Hospital, now recruiting.
Adebrelimab + Apatinib in SCLC Maintenance Therapy is a phase 2, interventional study registered as NCT06475209 by Tang-Du Hospital, with a registry enrolment figure of 60 participants, started 2024-06-20 and due to reach its primary completion in 2025-12-20. Interventions recorded: Adebrelimab combined with Apatinib. Conditions listed: SCLC. Primary outcome: Progression-free survival. Lung eligibility wording from the registry: "Histologically or cytologically confirmed extensive-stage small cell lung cancer (LS-SCLC) according to the AJCC 8th edition or VALG phase II staging criteria". Sites: China. No results are recorded here; the registry entry is the source.
Shares Adebrelimab, Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Adebrelimab, Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Adebrelimab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors, Immune checkpoint inhibitors and the tag lung-deep-dive.